Inspire Medical Systems is expected to report Q3 2026 revenue of $205.2 million and earnings per share of $0.10, while its current price of $192.35 sits below the average analyst target of $238.00.
The primary focus for investors this quarter is the commercial trajectory of the newly launched Inspire V system and its role in accelerating U.S. implant volumes.
This report follows recent clinical data suggesting that GLP-1 weight-loss drugs may complement rather than replace neurostimulation therapy for obstructive sleep apnea. Management’s updated guidance and commentary on surgeon utilization will be vital for sustaining investor confidence in the long-term growth story.